Can a second targeted drug still work after the first fails? new trial hopes to find out
Disease control
Recruiting now
This study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low) who have already received a similar drug called T-DXd. About 75 adults will receive SG at its standard dose. The goal is to …
Phase: PHASE2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC